 |
23 Diseases |  |
162 Trials |
|
162 Trials |  |
4758 News |  |
| «12...4849505152535455565758...6061» |
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial initiation date, Trial primary completion date: Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jan 24, 2018
P=N/A, N=3300, Not yet recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Dec 2017 --> Mar 2018 | Trial primary completion date: Apr 2023 --> Sep 2020
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie
New P3 trial, Combination therapy: A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy (clinicaltrials.gov) - Jan 23, 2018
P3b, N=100, Not yet recruiting, Sponsor: AbbVie
- ||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment closed: Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma (clinicaltrials.gov) - Jan 19, 2018
P2, N=64, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Dec 2017 --> Mar 2018 | Trial primary completion date: Apr 2023 --> Sep 2020 Recruiting --> Active, not recruiting
- || Tecentriq (atezolizumab) / Roche
Enrollment change, Combination therapy, Metastases: A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jan 17, 2018
P1, N=158, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting N=200 --> 158
- | Keytruda (pembrolizumab) / Merck (MSD), Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
New P2 trial, PD(L)-1 Biomarker: Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Jan 16, 2018
P2, N=37, Not yet recruiting, Sponsor: University of Washington
- | Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study. (Pubmed Central) - Jan 14, 2018
Change between baseline and end of IT in values of standardized uptake value and other PET parameters were associated with PFS and response. Validation of these results in prospective studies of larger cohorts is warranted.
- || Tecentriq (atezolizumab) / Roche
Enrollment closed, Combination therapy, Metastases: A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jan 10, 2018
P1, N=200, Active, not recruiting, Sponsor: Hoffmann-La Roche
Validation of these results in prospective studies of larger cohorts is warranted. Recruiting --> Active, not recruiting
- | Gazyva (obinutuzumab) / Roche, Biogen
Journal: Obinutuzumab Treatment of Follicular Lymphoma. (Pubmed Central) - Jan 2, 2018
Recruiting --> Active, not recruiting No abstract available
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial suspension: GIOTTO: Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients (clinicaltrials.gov) - Jan 2, 2018
P2, N=78, Suspended, Sponsor: Fondazione Italiana Linfomi ONLUS
No abstract available Recruiting --> Suspended
- |||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open, Combination therapy: PrE0403: Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy (clinicaltrials.gov) - Dec 21, 2017
P2, N=56, Recruiting, Sponsor: PrECOG, LLC.
Recruiting --> Suspended Not yet recruiting --> Recruiting
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment change, Combination therapy: A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Dec 20, 2017
P1, N=50, Recruiting, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting N=40 --> 50
- ||| avadomide (CC-122) / BMS
New P1 trial, Combination therapy: A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. (clinicaltrials.gov) - Dec 19, 2017
P1b, N=79, Recruiting, Sponsor: Celgene
- ||||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Trial completion: CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a) (clinicaltrials.gov) - Dec 19, 2017
P3, N=787, Completed, Sponsor: Hoffmann-La Roche
N=40 --> 50 Active, not recruiting --> Completed
- ||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial initiation date: Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response (clinicaltrials.gov) - Dec 18, 2017
P2, N=120, Recruiting, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Completed Initiation date: Jul 2016 --> Sep 2017
- || Brukinsa (zanubrutinib) / BeiGene
Enrollment change, Trial primary completion date, Combination therapy: BGB-3111_GA101_Study_001: BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies (clinicaltrials.gov) - Dec 18, 2017
P1b, N=132, Recruiting, Sponsor: BeiGene
Initiation date: Jul 2016 --> Sep 2017 N=86 --> 132 | Trial primary completion date: Jun 2017 --> Feb 2019 | N=86 --> 132 | Trial primary completion date: Jun 2017 --> Feb 2019 | N=86 --> 132 | Trial primary completion date: Jun 2017 --> Feb 2019
- ||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New trial: Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Dec 14, 2017
P=N/A, N=3300, Not yet recruiting, Sponsor: Hoffmann-La Roche
- |||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Biomarker, Trial completion, Combination therapy, Metastases: A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) (clinicaltrials.gov) - Dec 14, 2017
P2, N=100, Completed, Sponsor: Genentech, Inc.
N=86 --> 132 | Trial primary completion date: Jun 2017 --> Feb 2019 | N=86 --> 132 | Trial primary completion date: Jun 2017 --> Feb 2019 | N=86 --> 132 | Trial primary completion date: Jun 2017 --> Feb 2019 Active, not recruiting --> Completed
- | Tecentriq (atezolizumab) / Roche
New P1 trial, Combination therapy: A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov) - Dec 12, 2017
P1, N=42, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment closed: ICLL-07: Phase II Trial GA101 Inbrutinib B CLL (clinicaltrials.gov) - Dec 8, 2017
P2, N=12, Active, not recruiting, Sponsor: French Innovative Leukemia Organisation
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche, Tecentriq (atezolizumab) / Roche
Trial primary completion date, Combination therapy: A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Dec 5, 2017
P1, N=91, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2020 --> Sep 2021
- | Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Obinutuzumab is Effective in Chronic Lymphocytic Leukemia and Rheumatoid Arthritis After Rituximab Failure: A Case Report. (Pubmed Central) - Dec 3, 2017
CONCLUSIONS While anti-CD20 antibodies have a clear role in the treatment of leukemia and inflammatory conditions, the success of obinutuzumab in RA has not been fully evaluated. We present this case as further evidence of the strong role of anti-CD 20 therapy in multiple conditions, and the unique opportunity for control of simultaneous disease states through targeted inhibition of shared common pathways.
- | Gazyva (obinutuzumab) / Roche, Biogen
Journal: Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab. (Pubmed Central) - Nov 30, 2017
Obinutuzumab has an established safety profile in patients with CLL, but our case is the first reported case of a paraneoplastic, immune complex-mediated MPGN in CLL being treated with obinutuzumab. Obinutuzumab should be explored as a potential option in patients with CLL and MPGN.
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment change, Trial suspension: FIL_GAEL: GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Nov 30, 2017
P2, N=34, Suspended, Sponsor: Fondazione Italiana Linfomi ONLUS
Obinutuzumab should be explored as a potential option in patients with CLL and MPGN. N=78 --> 34 | Recruiting --> Suspended
- | Polivy (polatuzumab vedotin-piiq) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Phase classification, Combination therapy: GO29834: A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Nov 27, 2017
P1, N=128, Recruiting, Sponsor: Hoffmann-La Roche
N=78 --> 34 | Recruiting --> Suspended Phase classification: P1/2 --> P1
- || Polivy (polatuzumab vedotin-piiq) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial primary completion date, Combination therapy: GO29365: A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Nov 24, 2017
P1/2, N=225, Active, not recruiting, Sponsor: Hoffmann-La Roche
Phase classification: P1/2 --> P1 Trial primary completion date: Mar 2019 --> Apr 2017
- || Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial primary completion date, Combination therapy: A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Nov 21, 2017
P1, N=82, Active, not recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Mar 2019 --> Apr 2017 Trial primary completion date: Apr 2019 --> Apr 2018
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial primary completion date: NOBILITY: A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN) (clinicaltrials.gov) - Nov 14, 2017
P2, N=120, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Apr 2019 --> Apr 2018 Trial primary completion date: Aug 2019 --> Dec 2019
- ||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New P2 trial, Combination therapy: GAZAI: Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma (clinicaltrials.gov) - Nov 14, 2017
P2, N=93, Not yet recruiting, Sponsor: Heidelberg University
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment closed, Combination therapy: A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Nov 9, 2017
P1, N=92, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Aug 2019 --> Dec 2019 Recruiting --> Active, not recruiting
- || avadomide (CC-122) / BMS
Trial primary completion date, Combination therapy: A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. (clinicaltrials.gov) - Nov 6, 2017
P1b, N=79, Recruiting, Sponsor: Celgene
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2018 --> Dec 2018
- || Calquence (acalabrutinib) / AstraZeneca
Enrollment change, Trial primary completion date, Combination therapy: ACE-CL-003: Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL (clinicaltrials.gov) - Nov 6, 2017
P1b, N=72, Active, not recruiting, Sponsor: Acerta Pharma BV
Trial primary completion date: Jun 2018 --> Dec 2018 N=45 --> 72 | Trial primary completion date: Nov 2018 --> Jan 2022
- ||||| Brukinsa (zanubrutinib) / BeiGene
New P2 trial, Monotherapy: ROSEWOOD: A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma (clinicaltrials.gov) - Nov 6, 2017
P2, N=210, Recruiting, Sponsor: BeiGene
- | Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Biomarker, Clinical Trial,Phase I, Clinical Trial,Phase II, Clinical Trial,Phase III, Journal: Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. (Pubmed Central) - Nov 1, 2017
AEs reported with G were consistent with the known safety profile. Biomarker analyses may help define a future role for G in DLBCL.
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open: Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome (clinicaltrials.gov) - Oct 26, 2017
P1, N=10, Recruiting, Sponsor: University of California, San Diego
Biomarker analyses may help define a future role for G in DLBCL. Not yet recruiting --> Recruiting
- | Gazyva (obinutuzumab) / Roche, Biogen
New P2 trial: OLYMP-1: Obinutuzumab in Marginal Zone Lymphoma (clinicaltrials.gov) - Oct 26, 2017
P2, N=56, Not yet recruiting, Sponsor: Christian Buske
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, iladatuzumab vedotin (DCDS0780A) / Roche, Rituxan (rituximab) / Roche
Enrollment closed, Enrollment change, Combination therapy: A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Oct 25, 2017
P1, N=66, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=98 --> 66
- | Gazyva (obinutuzumab) / Roche, Biogen
Enrollment open: Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Oct 25, 2017
P2, N=32, Recruiting, Sponsor: University of Wisconsin, Madison
Recruiting --> Active, not recruiting | N=98 --> 66 Not yet recruiting --> Recruiting
- ||||| Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap, Neuraxpharm
Enrollment closed, Enrollment change, Combination therapy: UNITY-CLL: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Oct 19, 2017
P3, N=600, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=450 --> 600
- | Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells. (Pubmed Central) - Oct 18, 2017
Deregulation of ZAP-70 using tyrosine kinase inhibitors, gefitinib or ibrutinib, diminishes HA formation and trogocytosis by GA101. Taken together, these findings elucidate the differences in trogocytosis and HA formation mediated by anti-CD20 mAbs RTX and GA101, as well as provide a novel link between ZAP-70 expression and these effector functions.
- | Gazyva (obinutuzumab) / Roche, Biogen
New P2 trial: Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Oct 15, 2017
P2, N=32, Not yet recruiting, Sponsor: University of Wisconsin, Madison
- | Velexbru (tirabrutinib) / Ono Pharma, Gilead, entospletinib (GS-9973) / Kronos Bio
Enrollment change: Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Oct 13, 2017
P2, N=36, Recruiting, Sponsor: Gilead Sciences
Taken together, these findings elucidate the differences in trogocytosis and HA formation mediated by anti-CD20 mAbs RTX and GA101, as well as provide a novel link between ZAP-70 expression and these effector functions. N=60 --> 36
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Tecentriq (atezolizumab) / Roche
Trial suspension, Combination therapy: BO29562: A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma (clinicaltrials.gov) - Oct 3, 2017
P1, N=46, Suspended, Sponsor: Hoffmann-La Roche
N=60 --> 36 Recruiting --> Suspended
- || Velexbru (tirabrutinib) / Ono Pharma, Gilead
Trial primary completion date, Combination therapy: Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies (clinicaltrials.gov) - Oct 2, 2017
P1b, N=368, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Suspended Trial primary completion date: Dec 2018 --> Mar 2019
- || Trial primary completion date, Combination therapy: GO29833: A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Sep 25, 2017
P1, N=134, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2018 --> Mar 2019 Trial primary completion date: Jan 2021 --> Jun 2021
- || Polivy (polatuzumab vedotin-piiq) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: GO29834: A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Sep 25, 2017
P1/2, N=128, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jan 2021 --> Jun 2021 Trial primary completion date: Nov 2021 --> Mar 2022
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial primary completion date: A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities (clinicaltrials.gov) - Sep 13, 2017
P=N/A, N=50, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Nov 2021 --> Mar 2022 Trial primary completion date: Oct 2019 --> Apr 2020
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial primary completion date: Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov) - Sep 13, 2017
P1/2, N=72, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Oct 2019 --> Apr 2020 Trial primary completion date: May 2018 --> May 2019
- |||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Trial primary completion date, Metastases: A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) (clinicaltrials.gov) - Sep 12, 2017
P3, N=1401, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: May 2018 --> May 2019 Trial primary completion date: Feb 2017 --> Feb 2016
- | Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Tecentriq (atezolizumab) / Roche
New P2 trial: LYSA: Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas (clinicaltrials.gov) - Sep 7, 2017
P2, N=138, Not yet recruiting, Sponsor: The Lymphoma Academic Research Organisation
- || Velexbru (tirabrutinib) / Ono Pharma, Gilead
Trial primary completion date, Combination therapy: Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies (clinicaltrials.gov) - Sep 6, 2017
P1b, N=368, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Feb 2017 --> Feb 2016 Trial primary completion date: Jan 2020 --> Dec 2018